Objectives
Upon successful completion of this educational activity, participants should be better able to:

* Illustrate the evaluation of solitary pulmonary nodules,

* Discuss induction therapy for early stage NSCLC,
* Describe the management of tracheobronchial cancer,
* Define new concepts in targeted therapies for NSCLC,
* Assess STAT 3 and its role in thoracic malignancies,
* Review current trends in local and systemic treatment options for advanced NSCLC,
* Assess the role of race in the treatment of NSCLC,
* Evaluate minimally invasive surgical techniques for lung and esophageal cancers, and
* Examine surgical and nonsurgical treatment options and outcomes for the patient with mesothelioma.

Expected Results
It is the intent of our educational activity to provide physicians and allied health care providers with objective, evidence-based clinical content, which they can incorporate into their treatment strategies to improve the clinical care and outcomes for their patients with chest and esophageal malignancies.

Who Should Attend
Medical oncologists, radiation oncologists, pulmonologists, thoracic surgeons, general surgeons, diagnostic radiologists, internists, family practitioners and other allied health care professionals who treat patients with chest and esophageal malignancies.

Disclosure
This activity has been planned and implemented in strict accordance with the Essential Elements and Policies of the Accreditation Council for Continuing Medical Education (ACCME). City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

Prior to their participation in this City of Hope continuing medical education activity all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters specific commercial relationships and/or intent to discuss off-label and/or investigational use will be provided in the activity syllabus.

Acknowledgements
This Education Program is made possible through unrestricted educational grants. All companies who support this CME activity with educational grants will be acknowledged in the conference syllabus.